keyword
MENU ▼
Read by QxMD icon Read
search

Adjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/28433725/clinical-characteristics-and-surgical-treatment-of-spinal-paraganglioma-a-case-series-of-18-patients
#1
Mengchen Yin, Quan Huan, Zhengwang Sun, Shaohui He, Ye Xia, Wen Mo, Junming Ma, Jianru Xiao
BACKGROUND AND OBJECTIVES: Paraganglioma rarely develops in the spine. With few cases reported, little knowledge about this disease was known. The objective of this study is to illustrate the clinical features, imaging manifestations, pathological appearances and long-term outcomes of the consecutive surgeries by literature review. METHODS: The clinical and follow-up data of 18 patients who were diagnosed of spinal paraganglioma and treated with surgeries in our hospitals from 2003 to 2014 were retrospectively analyzed...
March 30, 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/28433254/does-adjuvant-therapy-improve-overall-survival-for-stage-ia-b-pancreatic-adenocarcinoma
#2
Katherine T Ostapoff, Emmanuel Gabriel, Kristopher Attwood, Boris W Kuvshinoff, Steven J Nurkin, Steven N Hochwald
BACKGROUND: Current guidelines recommend adjuvant chemotherapy for resected pancreatic adenocarcinoma (PDAC). However, no studies have addressed its survival benefit for stage I patients as they comprise <10% of PDAC. METHODS: Using the NCDB 2006-2012, resected PDAC patients with stage I disease who received adjuvant therapy (chemotherapy or chemoradiation) were analyzed. Factors associated with overall survival (OS) were identified. RESULTS: 3909 patients with resected stage IA or IB PDAC were identified...
April 19, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/28433225/adjuvant-chemotherapy-is-associated-with-improved-survival-in-locally-invasive-node-negative-non-small-cell-lung-cancer
#3
Usman Ahmad, Traves D Crabtree, Aalok P Patel, Daniel Morgensztern, Cliff G Robinson, A Sasha Krupnick, Daniel Kreisel, David R Jones, G Alexander Patterson, Bryan F Meyers, Varun Puri
BACKGROUND: The objectives of this study are to explore factors that are associated with use of adjuvant chemotherapy and to evaluate its impact on overall survival in node-negative patients who undergo lung and chest wall resection for non-small cell lung cancer (NSCLC). METHODS: Patients who underwent concomitant lung and chest wall resection for NSCLC were abstracted from the National Cancer Database. Clinical, pathologic, treatment, and follow-up data were obtained...
April 19, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28432588/patterns-of-care-and-outcomes-of-multi-agent-versus-single-agent-chemotherapy-as-part-of-multimodal-management-of-low-grade-glioma
#4
Waqar Haque, Vivek Verma, E Brian Butler, Bin S Teh
For high-risk low-grade gliomas (LGGs), adjuvant radiotherapy (RT) with procarbazine/lomustine/vincristine (PCV) chemotherapy increases overall survival (OS) over RT alone. However, in practice, temozolomide (TMZ) is often used instead of PCV. Using the National Cancer Data Base (NCDB), we provide the first investigation of practice patterns and outcomes of chemoradiotherapy with single-agent chemotherapy (SAC, analogous to TMZ) or multi-agent chemotherapy (MAC, analogous to PCV) for LGG. Patients with high-risk Grade II LGGs were queried in the NCDB...
April 21, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28432271/knockdown-of-prdx2-sensitizes-colon-cancer-cells-to-5-fu-by-suppressing-the-pi3k-akt-signaling-pathway
#5
Jun Xu, Shouru Zhang, Rong Wang, Xingye Wu, Li Zeng, Zhongxue Fu
Although, 5-Fluorouracil (5-FU) remains widely used in adjuvant therapy in patients with colon cancer, resistance to 5-FU-based chemotherapy is an important reason for treatment failure. Recent studies have reported that an enhanced reactive oxygen species (ROS) scavenging system shows drug resistance to 5-FU. Peroxiredoxin-2 (PRDX2), is an important member of the ROS scavenging system, and may be a potential target that promotes chemosensitivity to 5-FU in colon cancer. Here, we depleted PRDX2 by PRDX2-shRNA-LV transduction in two colon cancer cell lines and found that in vitro PRDX2 knockdown facilitates cell death and apoptosis in 5-FU-treated colon cancer cells...
April 21, 2017: Bioscience Reports
https://www.readbyqxmd.com/read/28431950/postoperative-adjuvant-chemotherapy-is-associated-with-a-lower-incidence-of-colorectal-adenomas-in-patients-with-previous-colorectal-cancer
#6
Hee Seung Lee, Sung Bae Kim, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Jae Hee Cheon, Won Ho Kim, Tae Il Kim
BACKGROUND AND AIMS: The effects of chemotherapeutic agents on the development of colorectal adenomas in patients with previous colorectal cancer (CRC) are not defined. Therefore, we evaluated the potential effect of adjuvant chemotherapy on the incidence of colorectal adenomas in patients with previous CRC. METHODS: We selected patients with low-risk stage II CRC with or without postoperative 5-fluorouracil-based adjuvant chemotherapy to reduce selection bias. Among 1808 patients with stage II CRC who underwent colonoscopic surveillance after curative resection of CRC between 2006 and 2013, 192 patients were retrospectively enrolled in this study after matching for age and sex...
April 18, 2017: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/28431518/is-adjuvant-chemotherapy-necessary-in-pt1n1-gastric-cancer
#7
Hyun Beak Shin, Ji Yeong An, Seung Hyoung Lee, Yoon Young Choi, Jong Won Kim, Soo Sang Sohn, Sung Hoon Noh
BACKGROUND: Due to a lack of consensus on adjuvant treatments for pT1N1 gastric cancer, surgeons face a dilemma when deciding treatments for patients with pT1N1 gastric cancer after gastrectomy. The objective of this study was to determine survival benefits of adjuvant chemotherapy and risk factors for tumor recurrence in gastric cancer patients with pT1N1. METHODS: Between 1996 and 2010, 510 patients who underwent curative resection for pT1N1 gastric cancer at three institutes were divided into two groups: adjuvant chemotherapy group (N = 150) and surgery-only group (N = 360)...
April 22, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28431392/characterization-of-aurora-a-and-its-impact-on-the-effect-of-cisplatin-based-chemotherapy-in-patients-with-non-small-cell-lung-cancer
#8
Peng Kuang, Zuhua Chen, JiaYuan Wang, Zhentao Liu, Jingyuan Wang, Jing Gao, Lin Shen
BACKGROUND AND OBJECTIVE: Aurora A, as a member of serine/threonine kinase family and a common characteristic of epithelial cancers, plays a critical role in cell mitosis. However, the clinical significance of Aurora A in non-small cell lung cancer (NSCLC) remains undetermined. METHODS: The expression of Aurora A in NSCLC and paired normal adjacent lung tissues was determined by immunohistochemistry, Western blot, and reverse transcriptase polymerase chain reaction...
April 18, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28431119/survival-benefit-of-adding-docetaxel-cisplatin-and-5-fluorouracil-induction-chemotherapy-to-concurrent-chemoradiotherapy-for-locally-advanced-nasopharyngeal-carcinoma-with-nodal-stage-n2-3
#9
Masahiro Kawahira, Tomoya Yokota, Satoshi Hamauchi, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida, Tetsuo Nishimura, Tetsuro Onitsuka, Hirofumi Yasui
Background: Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) has been established as the standard of care in locally advanced nasopharyngeal carcinoma (LA-NPC). The survival benefit of induction chemotherapy (ICT) for LA-NPC remains controversial. We analyzed the efficacy and feasibility of docetaxel, cisplatin and 5-fluorouracil (TPF) ICT followed by CCRT for LA-NPC with nodal Stage N2-3. Methods: We performed a retrospective analysis of 28 LA-NPC patients with nodal Stage N2-3 receiving induction TPF followed by CCRT (TPF group; n = 12) or CCRT-AC (CCRT group; n = 16) between October 2006 and May 2016...
April 20, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28430348/adjuvant-and-neoadjuvant-chemotherapy-for-soft-tissue-sarcomas-a-personal-point-of-view
#10
Robert S Benjamin
Dr. Gianni Bonadonna is internationally recognized as one of the foremost medical oncologists of the 20th century. He is best known for his pioneering work in the development of adjuvant chemotherapy for breast cancer, but he was also the father of sarcoma chemotherapy. The first investigator to study the new chemotherapeutic agent adriamycin in the late 1960s, he noted activity against sarcomas. This article, focusing on adjuvant chemotherapy, adriamycin, and sarcomas, memorializes his achievements and their progeny...
April 7, 2017: Tumori
https://www.readbyqxmd.com/read/28430288/mesenchymal-proangiogenic-factor-ykl-40-related-to-glioblastomas-and-its-relationship-with-the-subventricular-zone
#11
Kelvin M Pińa Batista, Sayoa Alvarez de Eulate-Beramendi, Kenia Y Álvarez Reyes de Pińa, Pedro Reimunde Figueira, Adan Fernandez Canal, Josué M Avecillas Chasin, Ángela Meilan, Rodrigo Ugalde, Ivan Fernandez Vega
<i>Glioblastoma is the most common primary brain tumor. Despite multimodality therapy with aggressive microsurgical resection and adjuvant chemotherapy and radiotherapy, the median survival is below 15 months. Glioblastomas are heterogeneous tumors with high resistance to most chemotherapeutic drugs. According to reliable evidence, YKL-40, one of the best investigated chitinase-like protein, may facilitate invasion, migration and angiogenesis, and could be also responsible for temozolomide resistance in glioblastoma, thus conferring a dismal prognosis...
2017: Folia Neuropathologica
https://www.readbyqxmd.com/read/28429473/surgery-for-limited-stage-small-cell-lung-cancer
#12
REVIEW
Hayley Barnes, Katharine See, Stephen Barnett, Renée Manser
BACKGROUND: Current treatment guidelines for limited-stage small-cell lung cancer (SCLC) recommend concomitant platinum-based chemo-radiotherapy plus prophylactic cranial irradiation, based on the premise that SCLC disseminates early, and is chemosensitive. However, although there is usually a favourable initial response, relapse is common and the cure rate for limited-stage SCLC remains relatively poor. Some recent clinical practice guidelines have recommended surgery for stage 1 (limited) SCLC followed by adjuvant chemotherapy, but this recommendation is largely based on the findings of observational studies...
April 21, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28428927/limitations-of-personalized-medicine-and-gene-assays-for-breast-cancer
#13
David Tiberi, Laura Masucci, Daniel Shedid, Isabelle Roy, Toni Vu, Erica Patocskai, André Robidoux, Philip Wong
Adjuvant systemic treatments reduce the risk of breast cancer recurrence following the local treatment of primary stage I-III breast cancers. For patients with hormone-positive breast cancers receiving hormonal therapy, the risk of distant recurrence is under 20% and therefore, many patients may potentially be spared of chemotherapy. Consequently, several molecular signatures based on gene expression were developed to better determine which breast cancer patients would benefit from chemotherapy. We present the case of a 62-year-old woman diagnosed with an early stage hormone receptor-positive breast cancer that was treated with a partial mastectomy...
March 17, 2017: Curēus
https://www.readbyqxmd.com/read/28428908/metastatic-squamous-cell-carcinoma-of-colon-from-esophageal-cancer
#14
Natasha Garg, Constance Stoehr, Yan Shi Zhao, Heather Rojas, Chung-Tsen Hsueh
BACKGROUND: Esophageal cancer including squamous cell carcinoma (SCC) and adenocarcinoma represents 4% of all cancers in the United States. Patients with esophageal cancer frequently present with locally advanced disease, and about 40% of patients have evidence of metastatic disease on presentation. Common sites of metastasis include liver, lung and bone. Here, we present a rare case of colonic metastasis from primary esophageal SCC. CASE PRESENTATION: A 60-year-old Caucasian male with a history of 20-pack-year cigarette smoking received surgery and adjuvant chemoradiotherapy for locally advanced SCC of larynx...
2017: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/28428516/-long-term-survival-of-a-gastric-neuroendocrine-carcinoma-patient-with-extra-regional-lymph-node-metastases
#15
Yosuke Ozawa, Naokazu Chiba, Kosuke Hikita, Masaaki Okihara, Toru Sano, Koichi Tomita, Kiminori Takano, Shigeyuki Kawachi
A 56-year-old man with advanced gastric tumor in the pyloric antrum had multiple lymph node metastases(lymph nodes #5, 6, 8, and 13), as revealed by abdominal computed tomography(CT).The patient was diagnosed with coexisting clinical Stage III A gastric cancer(cT2[SS], cN2, cM0)with concomitant malignant lymphoma.Distal gastrectomy, D2 lymph node dissection, and resection of lymph node #13 were performed.Histopathological findings indicated that both the primary tumor and lymph node metastases were neuroendocrine carcinomas...
April 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28428106/gata3-immunohistochemistry-in-urothelial-carcinoma-of-the-upper-urinary-tract-as-a-urothelial-marker-as-well-as-a-prognosticator
#16
Satoshi Inoue, Taichi Mizushima, Kazutoshi Fujita, Abdelrazak Meliti, Hiroki Ide, Seiji Yamaguchi, Hiroaki Fushimi, George J Netto, Norio Nonomura, Hiroshi Miyamoto
Immunohistochemistry of a transcription factor, GATA3, has been widely used as a promising urothelial marker in diagnostic surgical pathology practice. However, the expression status of GATA3 in upper urinary tract urothelial carcinomas (UUTUCs) and its prognostic significance have not been fully investigated. We immunohistochemically stained for GATA3 in 99 UUTUC samples and paired non-neoplastic urothelial tissues. GATA3 was positive in 51 [51.5%; 32 (32.3%) weak, 11 (11.1%) moderate, 8 (8.1%) strong] of 99 UUTUCs, which was significantly lower than in benign urothelium [79 (96...
April 17, 2017: Human Pathology
https://www.readbyqxmd.com/read/28428019/radiation-therapy-for-oropharyngeal-squamous-cell-carcinoma-executive-summary-of-an-astro-evidence-based-clinical-practice-guideline
#17
David J Sher, David J Adelstein, Gopal K Bajaj, David M Brizel, Ezra E W Cohen, Aditya Halthore, Louis B Harrison, Charles Lu, Benjamin J Moeller, Harry Quon, James W Rocco, Erich M Sturgis, Roy B Tishler, Andy Trotti, John Waldron, Avraham Eisbruch
PURPOSE: To present evidence-based guidelines for the treatment of oropharyngeal squamous cell carcinoma (OPSCC) with definitive or adjuvant radiation therapy (RT). METHODS AND MATERIALS: The American Society for Radiation Oncology convened the OPSCC Guideline Panel to perform a systematic literature review investigating the following key questions: (1) When is it appropriate to add systemic therapy to definitive RT in the treatment of OPSCC? (2) When is it appropriate to deliver postoperative RT with and without systemic therapy following primary surgery for OPSCC? (3) When is it appropriate to use induction chemotherapy in the treatment of OPSCC? (4) What are the appropriate dose, fractionation, and volume regimens with and without systemic therapy in the treatment of OPSCC? RESULTS: Patients with stage IV and stage T3 N0-1 OPSCC treated with definitive RT should receive concurrent high-dose intermittent cisplatin...
April 11, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28427822/reassessment-of-the-clinical-significance-of-portal-superior-mesenteric-vein-invasion-in-borderline-resectable-pancreatic-cancer
#18
S Hoshimoto, S Hishinuma, H Shirakawa, M Tomikawa, I Ozawa, S Wakamatsu, S Hoshi, N Hoshi, K Hirabayashi, Y Ogata
OBJECTIVE: The principal objective of this study is to clarify the prognostic significance of borderline resectable pancreatic cancer (BRPC). The second objective is to evaluate the prognostic impact of the depth of pathological venous invasion. METHODS: The study included 122 pancreatic cancer patients who underwent curative surgery. All computed tomography scans of the patients were retrospectively interpreted and classified according to the NCCN guidelines, version 1...
April 8, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28427506/recent-advances-in-genitourinary-tumors-a-review-focused-on-biology-and-systemic-treatment
#19
REVIEW
Aránzazu González Del Alba, José Ángel Arranz, Javier Puente, María José Méndez-Vidal, Enrique Gallardo, Enrique Grande, Begoña Pérez-Valderrama, Enrique González-Billalabeitia, Martín Lázaro-Quintela, Álvaro Pinto, Nuria Lainez, Josep M Piulats, Emilio Esteban, José Pablo Maroto Rey, Jorge A García, Cristina Suárez
Updated information published up to 2016 regarding major advances in renal cancer, bladder cancer, and prostate cancer is here presented. Based on an ever better understanding of the genetic and molecular alterations that govern the initial pathogenic mechanisms of tumor oncogenesis, an improvement in the characterization and treatment of urologic tumors has been achieved in the past year. According to the Cancer Genome Atlas (ATLAS) project, alterations in the MET pathway are characteristics of type 1 papillary renal cell carcinomas, and activation of NRF2-ARE pathway is associated with the biologically distinct type 2...
May 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28427503/oesophageal-cancer-which-treatment-is-the-easiest-to-swallow-a-review-of-combined-modality-treatments-for-resectable-carcinomas
#20
REVIEW
Bianca So, Loredana Marcu, Ian Olver, Raghu Gowda, Eva Bezak
Oesophageal cancer is a relatively uncommon malignancy, but with poor prognosis. Despite several treatment options that are available, the 5-year survival rates rarely exceed 40%. This review discusses the main challenges of oesophageal cancer, the available treatment options, and the most effective treatment in terms of overall survival. The outcomes of clinical trials show that neo-adjuvant chemo-radiotherapy using cisplatin and 5-fluorouracil followed by oesophagectomy results in the greatest survival. However, the optimal chemotherapy and radiotherapy schedule remains unclear...
May 2017: Critical Reviews in Oncology/hematology
keyword
keyword
12258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"